title: Oral tofacitinib for psoriasis: what happens with interrupted treatment?
authors.affiliation: Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC, 27104, U.S.A.. haliniamd@gmail.com.
authors.forename: H
authors.initials: H
authors.lastname: Alinia
authors.affiliation: Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC, 27104, U.S.A.|Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, 27104, U.S.A.|Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, 27104, U.S.A.
authors.forename: S R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D003879:Dermatologic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D010880:Piperidines / Q000008:administration & dosage*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011565:Psoriasis / Q000188:drug therapy*; D011743:Pyrimidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*
chemical_list: D003879:Dermatologic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles